• Something wrong with this record ?

De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors

T. Hornak, J. Mayer, P. Cicatkova, L. Semerad, A. Kvetkova, H. Klamova, E. Faber, P. Belohlavkova, M. Karas, L. Stejskal, E. Cmunt, O. Cerna, D. Srbova, H. Zizkova, L. Vrablova, I. Skoumalova, J. Voglova, T. Jurkova, M. Chrapava, T. Jurcek, I....

. 2024 ; 99 (4) : 763-766. [pub] 20240205

Language English Country United States

Document type Letter

Persistent link   https://www.medvik.cz/link/bmc24006560

Grant support
00023736 Ministerstvo Zdravotnictví Ceské Republiky
00669806 Ministerstvo Zdravotnictví Ceské Republiky
LX22NPO5102 Ministerstvo Školství, Mládeže a Tělovýchovy
MUNI/A/1558/2023 Ministerstvo Školství, Mládeže a Tělovýchovy

Overall survival of patients classified according to the European LeukemiaNet 2020 classification. Chronic phase (CP), accelerated phase (AP), blast crisis (BC), low risk (LR), intermediate risk (IR), high risk (HR).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006560
003      
CZ-PrNML
005      
20240423155344.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajh.27229 $2 doi
035    __
$a (PubMed)38317312
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hornak, Tomas $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000270033372
245    10
$a De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors / $c T. Hornak, J. Mayer, P. Cicatkova, L. Semerad, A. Kvetkova, H. Klamova, E. Faber, P. Belohlavkova, M. Karas, L. Stejskal, E. Cmunt, O. Cerna, D. Srbova, H. Zizkova, L. Vrablova, I. Skoumalova, J. Voglova, T. Jurkova, M. Chrapava, T. Jurcek, I. Jeziskova, M. Jarosova, K. Machova Polakova, T. Papajik, P. Zak, P. Jindra, D. Zackova
520    9_
$a Overall survival of patients classified according to the European LeukemiaNet 2020 classification. Chronic phase (CP), accelerated phase (AP), blast crisis (BC), low risk (LR), intermediate risk (IR), high risk (HR).
650    _2
$a lidé $7 D006801
650    12
$a inhibitory tyrosinkinasy $7 D000092004
650    12
$a chronická myeloidní leukemie $x farmakoterapie $7 D015464
650    _2
$a blastická krize $x farmakoterapie $7 D001752
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
655    _2
$a dopisy $7 D016422
700    1_
$a Mayer, Jiri $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic
700    1_
$a Cicatkova, Petra $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
700    1_
$a Semerad, Lukas $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
700    1_
$a Kvetkova, Anezka $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
700    1_
$a Klamova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Faber, Edgar $u Dpt. of Hemato-oncology, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic
700    1_
$a Belohlavkova, Petra $u 4th Dpt. of Internal Medicine and Hematology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000187287443
700    1_
$a Karas, Michal $u Dpt. of Hemato-oncology, University Hospital Pilsen and Charles University, Pilsen, Czech Republic
700    1_
$a Stejskal, Lukas $u Dpt. of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic $u Dpt. of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Cmunt, Eduard $u 1st. Internal Dpt, General University Hospital Prague, Prague, Czech Republic
700    1_
$a Cerna, Olga $u Dpt. of Hematology, University Hospital Kralovske Vinohrady and Charles University, Prague, Czech Republic
700    1_
$a Srbova, Dana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Zizkova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Vrablova, Lucia $u Dpt. of Hemato-oncology, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic
700    1_
$a Skoumalova, Ivana $u Dpt. of Hemato-oncology, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic
700    1_
$a Voglova, Jaroslava $u 4th Dpt. of Internal Medicine and Hematology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic
700    1_
$a Jurkova, Tereza $u Institute of Biostatistics and Analyses, Brno, Czech Republic
700    1_
$a Chrapava, Marika $u Institute of Biostatistics and Analyses, Brno, Czech Republic
700    1_
$a Jurcek, Tomas $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
700    1_
$a Jeziskova, Ivana $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
700    1_
$a Jarosova, Marie $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000221943433
700    1_
$a Machova Polakova, Katerina $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Papajik, Tomas $u Dpt. of Hemato-oncology, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic
700    1_
$a Zak, Pavel $u 4th Dpt. of Internal Medicine and Hematology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic
700    1_
$a Jindra, Pavel $u Dpt. of Hemato-oncology, University Hospital Pilsen and Charles University, Pilsen, Czech Republic
700    1_
$a Zackova, Daniela $u Dpt. of Internal Medicine Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000198028148 $7 xx0074334
773    0_
$w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 99, č. 4 (2024), s. 763-766
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38317312 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155341 $b ABA008
999    __
$a ok $b bmc $g 2080887 $s 1216327
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 99 $c 4 $d 763-766 $e 20240205 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
GRA    __
$a 00023736 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a 00669806 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a LX22NPO5102 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a MUNI/A/1558/2023 $p Ministerstvo Školství, Mládeže a Tělovýchovy
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options